Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05674513 · ClinicalTrials.gov registry record · Phase 4

Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

A Phase 4 study of Contraceptive Usage, sponsored by Oregon Health and Science University.

Recruiting
Registry status
Phase 4
Development phase
140
Enrollment target
1
Study location

NCT05674513 is a Phase 4 study of Contraceptive Usage that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 140 participants, below the 615-participant average among 11 other Contraceptive Usage trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05674513, a Phase 4 study of Contraceptive Usage, is actively recruiting participants, sponsored by Oregon Health and Science University.

RECRUITING
Registry status
Phase 4
Development phase
140 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.

Conditions Studied

Interventions

  • DRUG Ulipristal acetate

Study Locations (1)

Oregon

  • OHSU - Portland

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2023-01-09
Est. Completion 2027-12-31
Phase Phase 4

What the Registry Record Tells You About NCT05674513

The ClinicalTrials.gov registry entry for NCT05674513 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 615-participant average among 11 other Contraceptive Usage trials with a reported enrollment target (77% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Contraceptive Usage appearing as the primary indexed condition, and to 1 intervention - of which Ulipristal acetate is the first listed.

NCT05674513 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT05674513 about?

NCT05674513 is a clinical study titled "Disparities in Emergency Contraceptive Metabolism Dictate Efficacy". The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.

What is the current status of trial NCT05674513?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2023-01-09. Estimated completion is 2027-12-31.

What conditions does trial NCT05674513 study?

This clinical trial studies the following conditions: Contraceptive Usage.

What interventions are being tested in trial NCT05674513?

The interventions under investigation include: Ulipristal acetate (DRUG).

Who is sponsoring clinical trial NCT05674513?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05674513 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Contraceptive Usage

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.